Company files patent for treatment of chemotherapy-induced accelerated aging as a step towards treatment of other causes of aging.
Longevity biotech Immorta Bio has announced proof-of-concept findings supporting the potential of its personalized exosome technology to counteract chemotherapy-induced accelerated aging. The company says it has filed a patent application for its approach, which leverages patient-derived exosomes to rejuvenate damaged tissue and mitigate the cellular aging effects triggered by chemotherapy.
Immorta CEO Dr Boris Reznik said the company’s decision to focus on chemotherapy-induced accelerated aging was driven by a need to identify the therapeutic potential of its products “as quickly as possible.”
“By focusing on chemotherapy associated aging we can rapidly enter clinical trials and obtain anti-aging efficacy data of our product in a highly accelerated manner,” he added. “Successful results in this indication will allow us to expand to treating other causes of aging.”
Immorta’s approach aims to harness a patient’s own cells to create regenerative exosomes – biologically “young” stem cells designed to enable tissue rejuvenation. Unlike exosome therapies that rely on young donors, the company’s methodology involves extracting a patient’s blood and converting cells into immortalized “personal regenerative cells”, which are then grown in a controlled laboratory environment and further differentiated into mesenchymal stem cells with a defined biological age. From these cells, exosomes are harvested, providing a personalized source of regenerative nanoparticles designed to counteract aging and enhance tissue repair.
Speaking about the broad potential of exosomes in therapeutics, Immorta’s Chief Scientific Officer Dr Thomas Ichim said that “they transfer many of the regenerative activities of stem cells and do not possess the limitations associated with cell administration such as potential neoplasia or pulmonary accumulation.”
“Unfortunately, exosomes are limited by the fact they need to be collected from young sources,” he added. “The ImmortaSome exosomes are generated as ‘young’ exosomes from cells of the same patient that have been made ‘young’ in the laboratory.”
Beyond mitigating chemotherapy-induced aging, Immorta has previously reported that its approach may aid in cancer treatment by targeting senescent cells that surround tumors, a process believed to contribute to tumor growth and resistance to therapy. The newly announced exosome technology expands on this by offering a means of addressing the aging effects of cancer treatment while also holding promise for other age-related conditions.
With clinical trials planned for 2025, Immorta’s pipeline shows two lead therapeutic programs currently advancing toward the clinic. One targets liver failure, utilizing its PMSC-II repair cell and PPCH-01 liver progenitor cells, both of which have demonstrated preclinical efficacy. The other focuses on lung cancer, where the company says its SenoVax platform has shown potential in preclinical models by immunologically inactivating tumor-promoting senescent cells.
Photograph: Pressmaster/Envato